

**MAST CELLS AND NEUROENDOCRINE CELLS IN HUMAN AND RAT'S LUNG  
(A LITERARY REVIEW)**

**Ivelina Ivanova**

*Department of Anatomy, Faculty of Medicine, Trakia University, Stara Zagora, Bulgaria*

**Abstract**

The following review present scientific literature on lung mast cells and pulmonary neuroendocrine cells in Human and rat's lung Particular attention is paid to the location, morphology and arrangement of these cells in lung. Paul Ehrlich in 1878 (1) is the first author, who describe mast cells as effectors of allergy, particularly in the early and acute phases of allergic reactions. Ehrlich's initial view of mast cells, as metachromatic, granulated cells implicated in the nutrition of the surrounding tissue has change gradually during the years.

The detailed morphology of pulmonary neuroendocrine (NE) cells has been defined only during the last decade. The purpose of this paper is to present the main morphologic features of the NE cells, to review the location, development and functional significance of these cells.

**Keywords:** *mast cells, endocrine cells, lung*

**Introduction**

Mast cells are found in lung tissue in concentrations of 1-10 x 10<sup>6</sup> cells/g (2). They are widely spread in loose and dense connective tissues (3) such as the pleura, peribronchial areas and alveolar septa adjacent to nerves and blood vessels, particularly small arterioles and venules, and in the epithelium of upper and lower respiratory tract (4). Also they could be found free in the bronchial lumen (5, 6). Increased numbers of mast cells have been identified in humans in conditions of excessive pulmonary blood flow and chronic left ventricular decompensation (7), and in association with pulmonary fibrosis (8) as well. Whereas in rats, mast cells has been noted in chronic hypoxic states proliferation (9).

Pulmonary neuroendocrine cells (PNEC) are specialized airway epithelial cells that are found as solitary cells or as clusters called neuroepithelial bodies (NEB) in the lung. They are located in the nasal respiratory epithelium, laryngeal mucosa and in the entire respiratory tract from the trachea to the terminal airways. Both PNEC and NEB exist from fetal stage and neonatal stage in lungs airway area (10).

**Purpose and tasks**

The main purpose of this article is to present a literary review of the morphological characteristics of mast cells and endocrine cells in human and rat lung.

To achieve this aim, we set out the following main tasks:

1. To review our available literature related to mast cell and neuroendocrine cell morphology.
2. To present contemporary articles that are related to lung mast cell and neuroendocrine cell research.
3. To establish the current state of human and rat lung-related studies of mast cell endocrine cells.

**Literary review**

PNEC and NEB cells are bottle- or flask-like in shape, and reach from the basement membrane to the lumen. They can be distinguished by their profile of bioactive amines and peptides- serotonin, calcitonin, calcitonin gene-related peptide (CGRP), chromogranin A, gastrin-releasing peptide (GRP), and cholecystokinin. These cells can be a source of lung cancer- mostly, small cell carcinoma of the lung, and bronchial carcinoid tumor. More

specific cell markers are immunoreactivity to peptide hormones (bombesin, calcitonin, leu-enkephalin) identified so far in NE cells of human lung, and immunoreactivity to serotonin found in both human and animal lungs (11).

At the ultrastructural level, NE cells possess dense core granules (90-150 nm in diameter), consist of amine and peptide hormones (11).

The single NE cells are found throughout the tracheobronchial epithelium, whereas NEB are located only within the intrapulmonary airways (12).

PNEC function is connected to chemoreceptors in hypoxia detection. This is best supported by the presence of an oxygen-sensitive potassium channel coupled to an oxygen sensory protein in the luminal membrane. They are involved in regulating localized epithelial cell growth and regeneration through a paracrine mechanism. They also contain neuroactive substances which are released from basal cytoplasm and they induce autonomic nerve terminals or vasculature in the deep lamina propria (13).

In the fetal lung, they are frequently located at the branching points of airway tubules, and in humans are present by 10 weeks gestation. Peptides and amines released by PNEC are involved in normal fetal lung development including branching morphogenesis (14).

Two main types of mast cells are recognised in humans by their protease content. One population contains only tryptase (MCT) while the second one contains tryptase, chymase, carboxypeptidase A and cathepsin G (MCTC) (15). A rare third population containing only chymase (MCC) has also been reported (16, 17). Also a remarkably rapid conversion of MCTC cells to MCT has been found in co-culture with human airway epithelium (18). The MCT phenotype is typically located at mucosal surfaces such as the nasal and bronchial epithelium in rhinitis and asthma, and the bronchial lamina propria (19, 20). The MCTC phenotype is found in connective tissues such as normal skin, the airway smooth muscle bundles in asthma (21) and atherosclerotic lesions (22).

Andersson and colleagues (23) have performed a detailed immunohistochemical and morphological phenotypic analysis of mast cells in human lung. According to the shape, they prove more circular MCTC than MCT in all compartments except the alveoli. As in previous studies, MCT were the dominant cells in the airways and alveoli. MCTC were more common in the pleura.

The expression of the high-affinity IgE receptor and histidine decarboxylase was relatively high in airway MCT and MCTC, but absent in alveolar mast cells. Renin was highly expressed only in pulmonary vascular MCTC. Basic

FGF and VEGF were expressed in airway, alveolar and pulmonary vascular MCT, and large airway, and pulmonary vascular MCTC. It is proved that enzymatically dispersed parenchymal human lung mast cells with smaller diameter consistently release less histamine and PGD<sub>2</sub> than large mast cells following IgE-dependent activation (24).

Two subtypes of mature mast cells are described in rodents as well: mucosal mast cells (MMCs) and connective tissue mast cells (CTMCs) (25). In mouse, MMCs reside in the mucosal epithelium of the lung and gastrointestinal tract, and their protease content is characterized by the chymases mouse Mast Cell Proteases, mMCP-1 and mMCP-2, which are bound to chondroitin sulfate chains of serglycin proteoglycans, whereas CTMCs are found in the intestinal submucosa, peritoneum, and skin and contain the chymase mMCP-4, the tryptases mMCP-5 and mMCP-6, and carboxypeptidase A (mCPA) bound to heparin chains of serglycin proteoglycans (26, 27, 28, 29). MMCs and CTMCs also differ in their ability to secrete histamine and lipid mediators. Upon activation, MMCs release small amounts of histamine and large quantities of cysteinyl leukotrienes, whereas CTMCs release higher levels

of histamine and prostaglandin D (30).

It is proved that mast cell heterogeneity in peripheral tissues is much more dynamic than the two mast cell subsets traditionally described. For example both tracheal constitutive CTMCs and induced MMCs from sensitized mice analyzed by immunohistochemistry are presented with all six mast cell proteases (31).

### References

1. Ehrlich, P. Beiträge zur Theorie und Praxis der histologischen Färbung [Contribution to the theory and practice of histological dyes] (Dissertation) (in German). Leipzig University. OCLC 63372150, 1878.
2. Paterson, N. A. M., Wasserman, S. I., Said, J. W., and Austen, K. F. Release of chemical mediators from partially purified human lung cells. *J. Immunol.* 1976; 117: 1356-1362.
3. Kischer, C. W., Bunce, H., and Shetlar, M. R. Mast cell analyses in hypertrophic scars, hypertrophic scars treated with prednisone, and mature scars. *J. Invest. Dermatol.* 1978; 70: 355-357.
4. Feltkamp-Vroom, T. M., Stollman, P. J., Analberse, R. C., and Reerink-Bronkers, E. E. Immunofluorescence studies in renal tissue, tonsil, adenoids, nasal polyps, and skin of atopic and nonatopic patients, with special reference to IgE. *Clin. Immunol. Immunopathol.* 1975; 4: 392-404.
5. Tomita, A., Patterson, R., and Suszko, I. M. Respiratory mast cells and basophiloid cells. II. Effect of pharmacologic agents on 3<sup>5</sup>-adenosine monophosphate covalent and an antigen-induced histamine release. *Int. Arch Allergy.* 1974; 47: 261-272.
6. Patterson, R., McKenna, J. M., Suszko, I. M., Sulliday, N. J., Pruzansky, J. J., Roberts, M., and Kehoe, T. J. Living histamine containing cells from the bronchial lumens of humans. Description and comparison of histamine content with cells of rhesus monkeys. *J. Clin. Invest.* 1977; 59: 217-224.
7. Heath, D., Trueman, T., and Sukonthamarn, P. Pulmonary mast cells in mitral stenosis. *Cardiovasc. Pres.* 1969; 3: 467-471.
8. Watanabe, S., Watanabe, K., Ohishi, T., Aiba, M., and Kageyama, K. Mast cells in the rat alveolar septa undergoing fibrosis after ionizing irradiation: ultrastructure and histochemical studies. *Lab. Invest.* 1974; 31: 555-567.
9. Kay, J. M., Waymire, J. C. and Grover, R. E. Lung mast cell hyperplasia and pulmonary histamine-forming capacity in hypoxic rats. *Am. J. Physiol.* 1974; 226: 178-184.
10. Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. *Radiographics.* 2006; 26 (1): 41–57; discussion 57–8.
11. Cutz E. Neuroendocrine cells of the lung. An overview of morphologic characteristics and development. *Exp Lung Res.* 1982; 3(3-4): 185-208. Review.
12. Gould VE, Linnoila RI, Memoli VA, Warren WH. Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. *Lab Invest*, 1983; 49(5): 519-37.
13. Sunday ME. Oxygen, gastrin-releasing Peptide, and pediatric lung disease: life in the balance. *Front Pediatr*, 2014; 2: 72.
14. Aven L, Ai X. Mechanisms of respiratory innervation during embryonic development. *Organogenesis.* 2013; 9(3): 194-8.
15. Irani AM, Schwartz LB. Human mast cell heterogeneity. *Allergy Proc* 1994; 15: 303–8.
16. Weidner N, Austen KF. Ultrastructural and immunohistochemical characterization of

normal mast cells at multiple body sites. *J Invest Dermatol* 1991; 96: 26–30.

17. Bradding P, Okayama Y, Howarth PH, et al. Heterogeneity of human mast cells based on cytokine content. *J Immunol*, 1995; 155:297–307.

18. Hsieh FH, Sharma P, Gibbons A, et al. Human airway epithelial cell determinants of survival and functional phenotype for primary human mast cells. *Proc Natl Acad Sci USA*, 2005; 102:14380–5.

19. Irani AA, Schechter NM, Craig SS, et al. Two types of human mast cells that have distinct neutral protease compositions. *Proc Natl Acad Sci USA*, 1986; 83: 4464–8.

20. Bentley AM, Jacobson MR, Cumberworth V, et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. *J Allergy Clin Immunol*, 1992; 89: 877–83.

21. Brightling CE, Bradding P, Symon FA, et al. Mast cell infiltration of airway smooth muscle in asthma. *N Engl J Med* 2002; 346: 1699–705.

22. Jeziorska M, McCollum C, Woolley DE. Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries. *J Pathol*, 1997; 182: 115–122.

23. Andersson CK, Mori M, Bjermer L, et al. Novel sitespecific mast cell subpopulations in the human lung. *Thorax*, 2009; 64: 297–305.

24. Schulman ES, Kagey-Sobotka A, MacGlashan DW Jr, et al. Heterogeneity of human mast cells. *J Immunol*, 1983; 131: 1936–41.

25. Enerbäck L, Kolset SO, Kusche M, Hjerpe A, Lindahl U. Glycosaminoglycans in rat mucosal mast cells. *Biochem J*, 1985, 227: 661–668.

26. Musio S, Gallo B, Scabeni S, Lapilla M, Poliani PL, Matarese G, Ohtsu H, Galli SJ, Mantegazza R, Steinman L, Pedotti R. A key regulatory role for histamine in experimental autoimmune encephalomyelitis: disease exacerbation in histidine decarboxylase-deficient mice. *J Immunol*, 2006; 176: 17–26

27. Nagasaka A, Matsue H, Matsushima H, Aoki R, Nakamura Y, Kambe N, Kon S, Uede T, Shimada S. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. *Eur J Immunol*, 2008; 38: 48.

28. Yotsumoto K, Okoshi Y, Shibuya K, Yamazaki S, Tahara-Hanaoka S, Honda S, Osawa M, Kuroiwa A, Matsuda Y, Tenen DG, Iwama A, Nakauchi H, Shibuya A. Paired activating and inhibitory immunoglobulin-like receptors, MAIR-I and MAIR-II, regulate mast cell and macrophage activation. *J Exp Med*, 2003; 198: 223–233

29. Nagasaka A, Matsue H, Matsushima H, Aoki R, Nakamura Y, Kambe N, Kon S, Uede T, Shimada S. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. *Eur J Immunol*, 2008; 38: 489–499.

30. Hallgren J, Gurish MF. Pathways of murine mast cell development and trafficking: tracking the roots and routes of the mast cell. *Immunol Rev*, 2007; 17: 8–18.

31. Hsieh FH, Sharma P, Gibbons A, et al. Human airway epithelial cell determinants of survival and functional phenotype for primary human mast cells. *Proc Natl Acad Sci USA*, 2005; 102: 14380–5.